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Background  Remote ischemic conditioning(RIC) has been recognized an emerging 
non-invasive approach for preventing acute kidney injury(AKI) in patients undergoing either 
elective coronary artery bypass graft (CABG) surgery or percutaneous coronary intervention (PCI). 
On the other hand, accumulating evidence have indicated the involving role of pre-CABG contrast 
usage for coronary angiography in post-surgery AKI risk. Along with the shortening time delay of 
CABG after coronary angiography, and the prevalent hybrid coronary revascularization(HCR), the 
AKI prevention by RIC has faced challenges following coronary revascuralization. 
Methods Randomized controlled trials (RCTs) were searched from Pubmed, EMBase, and 
Cochrane library (until May 2016). The primary outcome was postoperative AKI. The second 
outcomes included the requirement for renal replacement therapy(RRT), and in-hospital or 30-day 
mortality.  
Results Twenty eligible RCTs (CABG, 3357 patients; PCI, 1501 patients) were selected. 
RIC significantly halved the incidence of AKI following PCI when compared with controls[n=1501; 
odds ratio(OR)= 0.51; 95% CI, 0.32 to 0.82; P=0.006; I2=29.6%]. However, RIC did not affect the 
incidence of AKI following CABG (n=1850; OR= 0.94; 95% CI, 0.73 to 1.19; P=0.586; I2=12.4%). 
The requirement for RRT and in-hospital mortality were not affected by RIC in CABG 
(n=2049,OR=1.04, P=0.87; n=1920, OR=0.89, P=0.7; respectively).  
Conclusions Our meta-analysis suggests that RIC for preventing AKI following CABG has 
faced with challenges in terms of AKI, the requirement for RRT, and mortality. However, RIC 
shows a renoprotective benefit for PCI. Hence, our findings may infer the preserved renal effects of 
RIC in CABG with preconditioning before the coronary angiography, or in HCR.  
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Introduction 
Acute kidney injury (AKI) following elective coronary artery bypass graft (CABG) surgery 
occurs up to 45% of patients and it is associated with increased medium- and long-term 
cardiovascular morbidity and mortality[1-5]. AKI after CABG has been attributed to reduced renal 
blood flow by cardiopulmonary bypass[6, 7] and hemodynamic instability. Contrast agent, regularly 
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used in percutaneous coronary intervention (PCI) [8-10], may also contribute to the risk of 
postoperative AKI in CABG patients undergoing pre-surgery coronary angiography[11-13]. This is 
an important issue given the shortening in the time interval between coronary angiography and 
CABG[11-13], and the increasing use of hybrid coronary revascularization(HCR) for multi-vessel 
coronary artery disease (CAD)[14, 15]. Therefore, novel strategies are needed to prevent AKI in 
patients undergoing CABG surgery. 
In 1993, Przyklenk et al[16] first demonstrated that regional ischemic preconditioning 
protected remote virgin myocardium of dogs against subsequent sustained coronary artery occlusion 
and reflow, implying the release of protective factors which can be transported to other organs to 
increase ischemic tolerance. This phenomenon has been termed ‘remote ischemic preconditioning’ 
(RIPC), and it can be induced non-invasively by simply inflating and deflating a standard blood 
pressure cuff placed on the upper arm or thigh. Experimental studies have shown that RIC confers 
renoprotection against acute ischemia/reperfusion (I/R) injury in numerous animal models[17-20]. 
Whether perioperative RIC can reduce the incidence of AKI in patients undergoing elective CABG 
remain unclear. 
Both single and multi-centre randomized controlled trials(RCT) have investigated the renal 
effect of RIC in the setting of CABG, but the results have been mixed[21-23] [24-26]. In contrast, 
evidence supporting the use of RIC as a renoprotective strategy in patients undergoing elective 
percutaneous coronary intervention (PCI) is increasing[27, 28], suggesting that RIPC may be 
beneficial in those patients undergoing pre-CABG coronary angiography or those undergoing PCI 
as a part of HCR strategy. Hence, we sought to comprehensively summarize the evidence for 
renoprotection of RIC both in CABG and PCI to highlight future opportunities for the use of RIC in 
the setting of CABG surgery. 
Methods 
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Search strategy and study criteria 
We searched English-published RCTs in PubMed, EMBase, and Cochrane Library (up to April 
2016), and scientific sessions (2012~2015) of American Heart Association (AHA), American 
College of Cardiology(ACC), and European Society of Cardiology (ESC) using keywords "remote 
ischemic conditioning", "coronary artery bypass graft", "percutaneous coronary intervention", 
"coronary revascularization", "kidney", and "renal". Invasive procedures were defined as elective 
CABG or PCI. Exclusion criteria were: ① studies not reporting one of the following endpoints: 
AKI and renal replacement therapy (RRT), and ② primary PCI.  
Literature review and data extraction  
The literature review and data extraction were independently completed by two investigators 
(Y.L. and H.P). Discussion was conducted for consensus in case of discrepancies. Quality 
assessment was completed according to the Jadad score: randomization; blinding; withdrawals and 
dropouts (a possible score between 0 and 5). Trials with a score of more than 3 were considered to 
be high-quality[29]. Data extraction included baseline patient characteristics (age, male, diabetes, 
history of MI, dyslipidemia, hypertension, baseline left ventricular ejection fraction, target 
vessels≥2, β-blockers usage, statins usage) as well as information pertaining to the RIC protocol 
(number cycles, ischemic time, and which limb), and follow-up time. 
Postoperative Outcomes and Definitions 
The primary endpoints was incidence of AKI within 7 days after CABG or PCI, defined as 
follows: ① a relative increase of >50% or an absolute increase of >0.3 mg/dL in serum creatinine 
from baseline, ② a relative increase of ≥25% or an absolute increase of ≥0.5 mg/dL in serum 
creatinine from baseline, ③ a relative decrease in estimated glomerular filtration rate >25% from 
baseline, ④ urinary liver-type fatty acid-binding protein (L-FABP) levels >17.4 μg/g serum 
creatinine levels].   
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The secondary outcomes includes in-hospital RRT, and all-cause mortality(in-hospital or 
within 30 days). 
Statistical analysis 
For dichotomous ones (reported with incidence), we calculated odds ratio (OR) with 95% 
confidence interval (CI). Random-effect model was used for the pooled analysis in the 
consideration of potential clinical inconsistency. The study with no event occurred in either of the 
two (treated or untreated) groups was excluded from the pooled analysis. When only one group of 
the study contained no events, a fixed value(0.5) was added to each cell of the 2X2 table for the 
pooled analysis. Publication bias was assessed by Begg’s test and Egger’s test for AKI. Sensitivity 
analyses were used to evaluate the robustness of our results by removing each included study at one 
time to obtain and assess the remaining overall estimates of AKI. Meta-regression and subgroup 
analyses were performed to explore the potential sources of heterogeneity and a P value of less than 
0.1 was accepted. P<0.05 (2-sided) was considered to be statistically significant for hypothesis 
testing. All statistical analyses were performed in Stata(version 11.0; Stata Corporation, College 
Station, TX). 
Results 
Study characteristics    
After 2119 abstracts were excluded from initial search due to duplication, review, experimental 
design, and other irrelevant content, Seventy-four potential studies were selected for detailed 
evaluation. Fifty-four studies were further excluded for the following reasons: valve surgery (n=7), 
vascular surgery(n=6), pediatric surgery (n=11), primary PCI(n=9), irretrievable or unclear data 
(n=3), nonrenal endpoints (n=10), ongoing trial (n=2), and endothelial trials (n=6). Twenty 
trials[21-28, 30-36]
,
[37-41] with a total of 4858 patients (n=2471 in RIC group) ultimately met our 
selection criteria, eleven[21-26, 30, 31, 34-36] of which were conducted for 3357 subjects in 
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elective CABG (Figure 1). The ischemic protocol (cycles×I/R) was 2~4×5min/5min in nineteen 
studies[21-26, 28, 30-36]
,
[37-41], and 4×30s/30s in one[27]. The upper limb was used in fifteen 
studies[21-23, 25, 26, 28, 30-33]
,
[37-41], the thigh in three[24, 34, 35], the combination of upper 
limb and thigh in one[36], and the heart in one[27]. The time interval between first cuff for remote 
conditioning to coronary reflow was 30~157 min in CABG, and several to 120 min in PCI. 
Perioperative AKI was reported in seventeen studies[21-25, 27, 28, 30-33, 36]
,
[37-41], RRT in ten 
[21-23, 25, 26, 30, 31, 34-36], and mortality in eight[21-23, 25, 26, 30, 31, 35].Seventeen studies
 [21, 22, 24-28, 30-36]
,
[37, 40, 41] had a Jadad score ≥3. Study design and patient 
characteristics are summarized in Table 1 and 2. 
Effect of RIC on the incidence of AKI  
The incidence of AKI following CABG was 31.4% (n=8 studies; RIC: 286/925;Control: 
295/925) and 9.1% in PCI (n=9 studies; RIC: 51/814;Control: 96/796). RIC lowered the risk of 
AKI in patients undergoing PCI (OR= 0.51; 95% CI, 0.32 to 0.82; P=0.006; I2=29.6%) but not in 
CABG (OR= 0.96; 95% CI, 0.76 to 1.20; P=0.695; I2=6.8%) (Figure 2A and 2B).  
The AKI stage I was reported in 1142 CABG patients with an overall incidence of 22.7%(n=6 
studies; RIC:128/583; Control: 131/559). RIC did not reduce the incidence of AKI stage I (OR= 
0.80; 95% CI, 0.49 to 1.31; P=0.377; I2=27.4%)(Figure 3A). 
Effect of RIC on the Requirement for RRT and Mortality 
The in-hospital RRT was reported in 2049 study subjects undergoing CABG, and the overall 
incidence was 3.1% (n=10 studies; RIC: 32/1033;Control: 31/1016). The requirement 
forpostoperative RRT was not reduced by RIC intervention(OR=1.04; 95% CI, 0.62 to 1.76; P=0.87; 
I2=0.0%)(Figure 3B).  
Mortality was reported in 1920 study subjects for CABG cohort , and the overall incidence was 
1.8% (n=8; RIC:17/972; Control:18/948). Mortality was nonsignificantly reduced with RIC 
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compared with control (OR=0.89, 95% CI: 0.45 to 1.76, P=0.74: I2=0.0%)(Figure 4) . 
Potential Sources of Heterogeneity 
Age, male (%), history of MI, diabetes (%), hypertension (%) , dyslipidaemia (%), contrast 
volume (ml),β-blockers(%), statins(%), and additive duration of ischemic conditioning(cycles time 
ischemic duration, min)were included in the random-effect univariate meta-regression analysis for 
AKI in PCI. As a result, the identified major sources of heterogeneity was additive duration of 
ischemic conditioning(min)(coefficient=-0.22; P=0.057; adjusted R2=1.00) for AKI. When 
compared with the 15-min subgroup, the 20-min subgroup demonstrated a significant reduction in 
the incidence of AKI levels [OR: 0.26  (P = 0.001) vs. 0.80 (P = 0.42); P = 0.02 for subgroup 
difference]. 
Discussion  
  In the present meta-analysis of 20 randomized trials enrolling 4858 CAD patients undergoing 
elective coronary revascularization, we found that RIC may offer renoprotection by reducing 
in-hospital AKI, especially in PCI. Moreover, increase in the number of RIC cycles may improve 
the clinical benefit for renal function by RIC. However, the effect of RIC on the requirement for 
RRT and mortality merits further investigations. 
 Revascularization type. Up to now, CABG and PCI remain two key therapeutic options for 
treating patients with stable CAD, and both are associated with substantial risk of AKI. There has 
always been a concern whether renoprotective therapies established in PCI can be translated into the 
setting of CABG. Clinical studies investigating periprocedural use of statins[6, 42], 
N-acetylcysteine[43, 44], sodium bicarbonate[45, 46], and erythropoietin[47, 48] have produced 
neutral results. In our meta-analysis,a higher rate of AKI in CABG (35.1% vs 9.1% in PCI) was 
observed, and the absolute risk reduction of post-procedural AKI by RIC was 0.8% in CABG and 
5.8% in PCI. This discrepancy may due to differences in the mechanisms of acute renal 
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injury(cardiopulmonary bypass and low CO in CABG versus contrast in PCI) [8-10], potential 
interference of volatile anesthetics[49], and higher rate of blood product transfusion during 
CABG[50]. Future studies should help elucidate the differential effects of RIC on renal injury. 
Optimal conditioning protocol. In the meta-analysis, the most widely used RIC protocol 
was 2~4 cycles of 5-min ischemia and reperfusion intervals of one unilateral limb achieved using a 
blood pressure cuff(inflated to ≥200mmHg or 50 mmHg> SBP). However, whether optimization in 
RIC protocol algorithm could confer renoprotective benefits remains unknown-for example 
combined conditioning in two remote organs[36], increase in the number of cycles, or a prolonged 
ischemic interval. In our investigation, the additive duration for ischemic conditioning in PCI is 
15min in six studies and 20 min in three one. Further regression analysis showed that additive 
duration was negatively correlated with risk of AKI(Ln-transformation), reducing by 0.22 per 1 min 
increase. This first intriguing indication for renal protection may provide some suggestion in the 
clinical setting of RIC.  
Optimal timing, new concept and clinical implication. It is also unknown how long RIC 
should be initiated before coronary revascularization to achieve renal benefit. RIC has been shown 
to elicit the protective effect in 2 different phases: early phase (<4 hours) and delayed phase 
(24~72hours)[51]. The time window in our analysis is quite wide-ranging (CABG, 30 ~157 min; 
PCI , several ~120 min). In our subgroup analysis, a dramatic difference in the effect of RIC on 
postprocedural AKI between CABG and PCI was obtained. How to improve the renal effect of RIC 
in patients undergoing CABG is an interesting issue. Recently, the pivotal role of time interval 
between coronary angiography and CABG surgery in postoperative AKI has been proposed in 
several large retrospective adjusted analyses[11-13]. The risk of AKI was highest in whom CABG 
was performed ≤1 day after cardiac catheterization, indicating that the underlying mechanisms of 
postprocedural AKI may be complicated with pre-existed contrast-induced injury. Based on these 
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evidence, the optimal timing for the reduction in CABG-associated AKI is a question that needs 
comprehensive consideration. The initiation of RIC before coronary angiography in patients waiting 
for CABG may be a new concept for preventing AKI in clinical practice.   
HCR has become a popular choice for its potential clinical benefit in selected patient with 
multivessel CAD. Although the off-pump technique itself has shown to provide better preservation 
of renal function than on-pump CABG[52, 53], AKI may be aggravated by simultaneous coronary 
angiography. Wang et al[54] using a propensity-matched analysis found a higher incidence of AKI 
in the hybrid group than that in the off-pump CABG(25.2% vs 17.6%). Our pooled analysis could 
add the potential renal evidence of translation for RIC in HCR in the future.    
 Strengths and Limitations. The strengths of this meta analysis include the main concern for 
renal outcomes, clinical sufficient consistency(restricted type of invasive procedures), and its ability 
in garnering a new large study population. On the other hand, several limitations should be pointed 
out for this study. Firstly, the potential influences of other co-morbidities (such as age, diabetes, and 
contrast volume)[27] and cardiovascular medications (such as β-blocker[55] ) may be 
underestimated. Secondly, the definitions for AKI varied trial from trial. Thirdly, AKI has been used 
as a surrogate endpoint to assess efficacy of RIC. However, there was no trend towards benefit with 
RIC in the hard renal outcomes such as hemodialysis or death. Lastly, the effect of RIC on 
long-term cardiovascular morbidity and mortality in elective coronary revascularization still need 
further evidence in future clinical trials.    
Conclusions 
Our meta-analysis suggests that RIC does not offer renoprotection during CABG surgery in 
terms of preventing AKI, reducing the requirement for RRT, and mortality. However, our study does 
show the renoprotective effect of RIPC in preventing AKI in patients undergoing elective PCI. 
Hence, our findings may infer the preserved renal effects of RIC in CABG with preconditioning 
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before the coronary angiography, or in HCR 
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Figure legends: 
Figure 1. Searching process for the eligible studies. RCT, randomized controlled trial; CABG, coronary artery 
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bypass graft; PCI, percutaneous coronary intervention. 
Figure 2. Forest plot for in-hospital acute kidney injury(AKI) in elective CABG (A) or PCI (B).RIC, remote 
ischemic conditioning. Ctrl, control. 
Figure 3. Forest plot for in-hospital AKI stage I (A) and requirement of renal replacement therapy(B) in elective 
CABG.. RIC, remote ischemic conditioning. Ctrl, control. 
Figure 4. Forest plot for mortality in elective CABG.. RIC, remote ischemic conditioning. Ctrl, control. 
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 Study 
Country 
Surgery 
Pts. No. 
RIC vs Ctrl 
           RIC protocol 
RIC initiation to 
invasive procedure 
Placebo 
Control 
Renal 
Endpoints 
 Baseline  
F-up 
Jadad  
score 
Cycles×I/R Cuff pressure  Creatinine 
level(mg/dl) 
AKI Definition 
Rahman 2010[21] UK CABG(On) 42 vs 38 3×5min/5min at upper limb 200mmHg 74 mins Yes AKI, RRT, Mortality 1.10 SCr↑>0.5 mg/dl 30 d 5 
Venugopal 2010[22] UK CABG(On) 35 vs 32 3×5min/5min at upper limb 200mmHg <45~60mins Yes AKI,RRT,Mortality 0.95 SCr↑≥50% or ≥0.3 mg/dl 30 d 4 
Young 2012[31] 
 
New 
Zealand 
CABG(On) 
(Substudy) 
9 vs 9 3×5min/5min at upper limb 200mmHg N.A Yes AKI, RRT, Mortaltiy 1.10 SCr↑≥50% or eGFR ↓≥25% 30 d 5 
Lucchinetti 2012[34] Canada CABG (On) 27 vs 28 4×5min/5min at thigh 300mmHg N.A Yes RRT 1.01 RRT 6 mon 5 
Hong 2012[35] Korea CABG(Off) 35 va 35 4×5min/5min at thigh 200mmHg 18 mins     Yes RRT, Mortality 1.10 RRT 30 d 3 
Hong 2014[24] 
 
Korea CABG(Off) 
(Substudy) 
267 vs 289 4×5min/5min at thigh 200mmHg N.A Yes AKI N.A SCr↑≥50% or ≥0.3 mg/dl In-hospital 5 
Gallagher 2014[23] UK CABG 43 vs 43 3×5min/5min at upper limb 50mmHg > 
SBP 
N.A Yes AKI, RRT, Mortality 1.37 SCr↑≥50% or ≥0.3 mg/dl 30 d 2 
Candilio 2014[36] UK CABG(On) 
(Substudy) 
57 vs 54 2×5min/5min at upper limb and thigh 200mmHg <45mins Yes AKI, RRT N.A SCr↑≥50% or ≥0.3 mg/dl In-hospital 5 
Hausenloy 2015[25] UK CABG(On) 
(Substudy) 
395 vs 385 4×5min/5min at upper limb 200mmHg 105 min Yes AKI, RRT, Mortality N.A SCr↑≥50% or ≥0.3 mg/dl In-hospital 5 
Zarbock 2015[30] German CABG(On) 
(Substudy) 
44 vs 36 3×5min/5min at upper limb 200mmHg or 
50mmHg > 
SBP 
N.A Yes AKI, RRT, Mortality 1.15 SCr↑≥50% or ≥0.3 mg/dl In-hospital 5 
Meybohm 2015[26] German CABG(On) 
(Substudy) 
313 vs 317 4×5min/5min at upper limb ≥200mmHg 
or 15mmHg > 
SBP 
N.A Yes RRT, Mortality N.A SCr↑≥50% or ≥0.3 mg/dl In-hospital 5 
Hoole 2009[32] UK PCI 104 vs 98 3×5min/5min at upper limb 200mmHg 96.0 mins Yes AKI N.A SCr↑> 25% 24h 4 
Er 2012[41] Germany PCI 50 vs 50 4×5min/5min at upper limb 50mmHg > 
SBP 
40.0 to 85.0 mins Yes AKI 1.63 SCr↑≥25% or ≥0.5 mg/dl 48h 5 
Igarashi 2013[33] Japan PCI 30 vs30 4×5min/5min at upper limb 200mmHg 120min No AKI 1.13 Urinary L-FABP↑>25% or >17.4 μg/g SCr  48h 3 
Luo 2013[40] China PCI 101 vs 104 3×5min/5min at upper limb 200mmHg <120.0 mins Yes AKI 
  
N.A SCr↑> 25% 16 h 3 
Deftereos 2013[27] Greece PCI 113 vs 112 4×30s/30s at heart  <3 atm Immediately Yes AKI 1.0 SCr↑≥ 25% or ≥0.5 mg/dl 96h 3 
Xu 2013[37] China PCI 102 vs 98 3×5min/5min at upper limb 200mmHg 30.0 to 120.0 mins No AKI 0.86 SCr↑> 25% 16 h 5 
Savaj 2014[38] Iran PCI 48 vs 48 3×5min/5min at upper limb 200mmHg 15 mins No AKI 1.19 SCr↑≥ 30% or ≥0.3mg/dl 24h 1 
Lavi 2014 I[28] Canada PCI 120 vs 120 3×5min/5min at upper limb 200mmHg or 
50mmHg > 
SBP 
Several mins after 
PCI 
Yes AKI N.A SCr↑> 25% or >0.5 mg/dl 24 h 5 
Lavi 2014 II[28] Canada PCI 120 vs 120 3×5min/5min at thigh 200mmHg or 
50mmHg > 
SBP 
Several mins after 
PCI 
Yes AKI N.A SCr↑> 25% or >0.5 mg/dl 24 h 5 
Menting 2015[39] Netherland PCI 38 vs 38 4×5min/5min at upper limb 50mmHg > 
SBP 
<45.0 mins Yes AKI 1.32 SCr↑≥25% or ≥0.5 mg/dl 72h 2 
Table 1 Study design in all included randomized trials 
Table 1
 Note: CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; I/R, ischemia/reperfusion; SBP, systolic blood pressure; atm, atmosphere; AKI, acute kidney injury; RRT, renal replacement treatment; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; L-FABP, liver-type fatty acid-binding 
protein; N.A, not available; RIC, remote ischemic conditioning; Ctrl, control.  
  
 
Table 2 Patient characteristics in all included randomized trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Note: MI, myocardial infarction; HT, hypertension; LVEF, left ventricular ejection fraction; N.A, not available.  
 
 
 
 Note: Pre-MI, previous myocardial infarction; DM, diabetes mellitus; HT, hypertension; CPB, cardiopulmonary bypass; eGFR, estimated glomerular filtration rate; LVEF,  left ventricular ejection fraction; N.A, not 
available. 
Substudy Age 
Male(
%) 
Pre-MI 
(%) 
DM 
(%) 
HT 
(%) 
Dyslipid
emia 
(%) 
Renal 
dysfunction 
(%) 
CPB 
duration
(min)  
Contrast  
Dose(ml) 
Baseline 
LVEF(%) 
Target  
Vessels≥2 
(%) 
β-blockers 
 (%) 
Statins 
(%) 
Rahman 2010[21] 64.0 88.5 0.0 0.0 59.3 74.1 N.A 98 / 60.1 100.0 81.0 88.0 
Venugopal 2010[22] 65.0 82.0 23.0 0.0 65.4 75.6 N.A 86 / N.A 96 55 79.5 
Young 2012[31] 
 
66.4 62.5 27.8 N.A N.A 60.4 N.A 111.1 / N.A 57.3 66.7 60.4 
Lucchinetti 2012[34] 60.5 91.0 41.8 0.0 70.9 85.5 N.A 101 / 52.0 100.0 91.0 96.0 
Hong 2012[35] 64.7 72.9 N.R 35.7 68.6 17.1 0 54 / ≥30.0 100.0 64.3 72.9 
Hong 2014[24] 
 
60.8 61.3 7.3 30.2 48.6 53.8 3.1 159.7 / 57 N.A 42.7 N.A 
Gallagher 2014[23] 70.8 80.2 52.3 64.0 82.6 77.9 N.A 94 / 52 96.5 35 91.9 
Candilio 2014[36] 65.5 78.1 28.7 29.2 78.8 74.2 0 93.2 / N.A 93.1 74.2 80.9 
Hausenloy 2015[25] 76.2 70.8 39.5 25.7 74.5 69.8 0 70.0 / N.A N.A N.A N.A 
Zarbock 2015[30] 70.4 62.9 0 37.5 96.7 N.A 30.9 118 / N.A N.A 73.0 82.5 
Meybohm 2015[26] 66.0 74.2 28.9 24.8 N.A N.A 11.2 N.A / N.A N.A 63.2 65.5 
Hoole 2009[32] 62.5 78.2 55.4 21.8 51.5 N.A N.A / 192.2 50.2 16.8 79.2 95.0 
Er 2012[41] 71.1 71.7 N.A 33.3 N.A N.A eGFR:30~60
(48.2) 
/ 92.4 N.A N.A 43.3 75.0 
Igarashi 2013[33] 73.0 71.0 41.0 64.0 91 75.0 eGFR< 
60(38.3) 
/ 113.5 59.6 N.A 82.0 N.A 
Luo 2013[40] 59.3 76.1 21.5 27.8 65.9 N.A eGFR=100 / 149.4 64.0 27.8 82.4 N.A 
Deftereos 2013[27] 68 64.0 N.A 36 65 59 eGFR>60(75
) 
/ 270 56 55.1 17 36 
Xu 2013[37] 69.0 68.0 23.0 100.0 63.5 N.A eGFR=99.9 / 167.6 63.7 N.A 80.0 100.0 
Savaj 2014[38] 62 32.3 16.7 100 70.9 N.A eGFR>50(86
.5) 
/ 125.2 N.A N.A N.A N.A 
Lavi 2014 I[28] 63.7 72.9 43.0 32.5 70.0 67.0 eGFR>30 / 187.5 N.A 18.8 N.A N.A 
Lavi 2014 II[28] 64.3 74.2 42.0 29.5 70.0 65.0 eGFR>30 / 187.5 N.A 21.67 N.A N.A 
Menting 2015[39] 72 48.5 40 25 72.5  N.A eGFR=51 / 98.5 N.A N.A 65.5 N.A 
Table 2
